Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Health Technology Assessment

• Publication date

  2011-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3310/hta15380PMID 22059955PMCID PMC4781160
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarkers of liver fibrosis.

  2013cited by this paper
• Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.

  2013cited by this paper
• Metabolic and Additional Vascular Effects of Thiazolidinediones

  2012cited by this paper
• Biomarkers of liver fibrosis

  2011cited by this paper
• Systematic reviews and meta-analyses.

  2011cited by this paper
• Liraglutide for the treatment of type 2 diabetes.

  2011cited by this paper
• Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study

  2011cited by this paper
• NIHR Health Technology Assessment programme

  2011cited by this paper
• Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial.

  2010cited by this paper
• Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study

  2010cited by this paper
• Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

  2010cited by this paper
• High prevalence of advanced NAFLD in type 2 diabetic patients with unremarkable liver enzymes and effect of liraglutide on NAFLD: meta-analysis of the LEAD Program

  2010cited by this paper
• Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients

  2010cited by this paper
• The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease

  2010cited by this paper
• Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

  2010cited by this paper
• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  2010cited by this paper
• Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data

  2010cited by this paper
• Symptoms and quality of life in obese children and adolescents with non‐alcoholic fatty liver disease

  2010cited by this paper
• A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

  2010cited by this paper
• The state of obesity and obesity research.

  2010cited by this paper
• Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes

  2010cited by this paper
• Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

  2010cited by this paper
• Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee.

  2010cited by this paper
• Trends in the prevalence and incidence of diabetes in the UK: 1996–2005

  2009cited by this paper
• Metabolic disturbances in non-alcoholic fatty liver disease.

  2009cited by this paper
• Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sonography().

  2009cited by this paper
• Treatment of non‐alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin‐resistant adolescents

  2009cited by this paper
• Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance.

  2009cited by this paper
• Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

  2009cited by this paper
• New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)

  2009cited by this paper
• Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?

  2009cited by this paper
• Recent advances in nonalcoholic fatty liver disease

  2009cited by this paper
• Methods for assessing intrahepatic fat content and steatosis

  2009cited by this paper
• Noninvasive diagnosis of nonalcoholic fatty liver disease.

  2009cited by this paper
• Imaging-based quantification of hepatic fat: methods and clinical applications.

  2009cited by this paper
• Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network

  2009cited by this paper
• Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial

  2009cited by this paper
• Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis.

  2009cited by this paper
• The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial

  2009cited by this paper
• The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

  2009cited by this paper
• New imaging techniques for non-alcoholic steatohepatitis.

  2009cited by this paper
• Pharmacological Interventions for Nonalcoholic Fatty Liver Disease in Adults and in Children: A Systematic Review

  2009cited by this paper
• Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis.

  2008cited by this paper
• FibroTest-ActiTest as a non-invasive marker of liver fibrosis.

  2008cited by this paper
• Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?

  2008cited by this paper
• Non-invasive diagnosis of steatosis and fibrosis.

  2008cited by this paper
• Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography

  2008cited by this paper
• Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive

  2008cited by this paper
• How much loss to follow-up is acceptable in long-term randomised trials and prospective studies?

  2008cited by this paper
• Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.

  2008cited by this paper
• A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis

  2008cited by this paper
• Biomarkers of liver fibrosis.

  2008cited by this paper
• Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation.

  2008cited by this paper
• Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause

  2008cited by this paper
• Clinical trial: insulin‐sensitizing agents may reduce consequences of insulin resistance in individuals with non‐alcoholic steatohepatitis

  2008cited by this paper
• Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations.

  2008cited by this paper
• Liver fibrosis.

  2008cited by this paper
• Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.

  2008cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  2007cited by this paper
• Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question.

  2007cited by this paper
• Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study.

  2007cited by this paper
• Pathogenesis of NASH: animal models.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Health‐related quality of life in patients with non‐alcoholic fatty liver disease

  2007cited by this paper
• The Epidemiology and Risk Factors of NASH

  2007cited by this paper
• Incidence and natural course of fatty liver in the general population: The Dionysos study

  2007cited by this paper
• Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study

  2007cited by this paper
• Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies.

  2007cited by this paper
• Effects of bariatric surgery on nonalcoholic fatty liver disease: Preliminary findings after 2 years

  2007cited by this paper
• Benefits of lifestyle modification in NAFLD

  2007cited by this paper
• Pathogenesis of non-alcoholic steatohepatitis: human data.

  2007cited by this paper
• Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients

  2007cited by this paper
• Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients

  2007cited by this paper
• Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.

  2007cited by this paper
• Role of radiologic modalities in the management of non-alcoholic steatohepatitis.

  2007cited by this paper
• Effect of Pioglitazone Therapy on Myocardial and Hepatic Steatosis in Insulin-Treated Patients with Type 2 Diabetes

  2007cited by this paper
• Resolution of Nonalcoholic Steatohepatits after Gastric Bypass Surgery

  2007cited by this paper
• Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs.

  2007cited by this paper
• Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation.

  2006cited by this paper
• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  2006cited by this paper
• LIVER FAILURE AND LIVER DISEASE Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis

  2006cited by this paper
• Statins and hepatic steatosis: Perspectives from the Dallas Heart Study

  2006cited by this paper
• Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence

  2006cited by this paper
• Non-alcoholic fatty liver disease: current concepts and management strategies.

  2006cited by this paper
• Long-term outcome of bariatric surgery: an interim analysis.

  2006cited by this paper
• Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.

  2006cited by this paper
• Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.

  2006cited by this paper
• Natural History of Nonalcoholic Steatohepatitis

  2006cited by this paper
• Weight Loss and Non-alcoholic Fatty Liver Disease: Falls In Gamma-Glutamyl Transferase Concentrations are Associated with Histologic Improvement

  2006cited by this paper
• Pathophysiology of nonalcoholic steatohepatitis.

  2006cited by this paper
• Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB

  2005cited by this paper
• A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease

  2005cited by this paper
• Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.

  2005cited by this paper
• Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets.

  2005cited by this paper
• The associations of physical activity and adiposity with alanine aminotransferase and gamma-glutamyltransferase.

  2005cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Non‐alcoholic Steatohepatitis

  2005cited by this paper
• Natural history of NAFLD: remarkably benign in the absence of cirrhosis.

  2005cited by this paper
• Season of mist and, hopefully, mellow fruitfulness

  2005cited by this paper
• Nonalcoholic fatty liver disease and the metabolic syndrome

  2005cited by this paper

• Dietary supplement based on dihydromyricetin in metabolic dysfunction-associated steatotic liver disease: a double-blind, placebo-controlled, randomized clinical trial

  2025cites this paper
• Clinical model to predict the risk of nonalcoholic fatty liver disease: A secondary analysis of data from a cross-sectional study

  2024cites this paper
• Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology

  2022cites this paper
• Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease

  2022cites this paper
• To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases

  2022cites this paper
• The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules

  2022cites this paper
• The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

  2022cites this paper
• Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.

  2022cites this paper
• Chlorogenic Acid and Geniposide Combination Prevents NASH in Rats Fed High-fat diet via Microbiota and TLR4-LPS Pathway

  2021cites this paper
• Evaluating proposed surrogates to estimate insulin resistance in non-diabetics: emphasizing the ratio triglycerides/HDL-cholesterol versus fasting blood glucose

  2020cites this paper
• Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials.

  2020cites this paper
• Antidepressant use and orthostatic hypotension in older adults living with mild‐to‐moderate Alzheimer disease

  2020cites this paper
• The impact of depression, self-esteem, and body image on sleep quality in patients with PCOS: a cross-sectional study

  2019cites this paper
• Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease

  2019cites this paper
• The Importance of Auxology for Growth Assessment

  2019cites this paper
• Dietary intake and lifestyle behaviour in different phenotypes of polycystic ovarian syndrome: a case-control study.

  2019cites this paper
• Circulating ALT Levels in Healthy Volunteers Over Life-Span: Assessing Aging Paradox and Nutritional Implications

  2019cites this paper
• Therapy to Obese Type 2 Diabetes Mellitus: How Far Will We Go Down the Wrong Road?

  2018cites this paper
• Examining the Relationship Between Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome in Nondiabetic Subjects

  2018cites this paper
• Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study

  2018cites this paper
• Regular Exercise as a Secondary Practical Treatment for Nonalcoholic Fatty Liver Disease

  2018influential citation
• Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.

  2017cites this paper
• Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.

  2017cites this paper
• Esteatosis hepática no alcohólica en pacientes con síndrome metabólico

  2017cites this paper
• Nutrient intake of patients with non-alcoholic fatty liver disease in Dhaka city, Bangladesh

  2017cites this paper
• Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease

  2017cites this paper
• Comparación de los factores de riesgo cardiovascular, adipocitoquinas, antropometría e ingesta dietética de pacientes obesos con ALT/GPT alterada frente a pacientes obesos con ALT/GPT normal

  2017cites this paper
• Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study

  2017influential citation
• The effect of exercise in NAFLD and a GLP-1 receptor agonist in type 2 diabetes on lipid metabolism.

  2016cites this paper
• Physiological and Pathological Interactions Between Liver and Kidney

  2016cites this paper
• The effect of silymarin on non-alcoholic fatty liver disease of children

  2016cites this paper
• Non-alcoholic Fatty Liver Disease in Obesity

  2016cites this paper
• Jiang Tang Xiao Ke Granule, a Classic Chinese Herbal Formula, Improves the Effect of Metformin on Lipid and Glucose Metabolism in Diabetic Mice

  2016cites this paper
• Hypoglycemic agents and potential anti-inflammatory activity

  2016cites this paper
• Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.

  2016cites this paper
• Non-Alcoholic Fatty Liver Disease (NAFLD): The Search for a Cure

  2016cites this paper
• Chokeberry attenuates the expression of genes related to de novo lipogenesis in the hepatocytes of mice with nonalcoholic fatty liver disease.

  2016cites this paper
• Effect of Jungmanbunso-hwan Extract on HepG2 Cell Model of Nonalcoholic Fatty Liver Disease Caused by Palmitate

  2016cites this paper
• Oxidative stress and neuropsychiatric disorders in the life spectrum

  2016cites this paper
• Treatment strategies for fatty liver diseases.

  2015cites this paper
• Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future

  2015cites this paper
• Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

  2015cites this paper
• Cuantificación y monitorización del hígado graso no alcohólico mediante resonancia magnética

  2015cites this paper
• Roles for PI 3 K / AKT / PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease

  2015cites this paper
• Non-alcoholic fatty liver disease and type 2 diabetes : An overview of the problem

  2015cites this paper
• Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats

  2015cites this paper
• Non Alkolik Yağlı Karaciğer Hastalığında Güncel Medikal Tedavi

  2015cites this paper
• Peroxisomes compensate hepatic lipid overflow in mice with fatty liver.

  2015cites this paper
• Non-Alcoholic Fatty Liver Disease and Prediabetes

  2015cites this paper
• Metformin prevents ischemia reperfusion-induced oxidative stress in the fatty liver by attenuation of reactive oxygen species formation.

  2015cites this paper
• Breast magnetic resonance imaging (MRI) surveillance in breast cancer survivors

  2015cites this paper
• New Therapeutic Approaches to Prevent or Delay Beta-Cell Failure in Diabetes

  2015cites this paper
• Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial.

  2015cites this paper
• Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease.

  2015cites this paper
• Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

  2014cites this paper
• Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism

  2014cites this paper
• Regular Exercise Coupled to Diet Regimen Accelerates Reduction of Hepatic Steatosis and Associated Pathological Conditions in Nonalcoholic Fatty Liver Disease

  2014cites this paper
• The role of medications for the management of patients with NAFLD.

  2014cites this paper
• Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

  2014cites this paper
• Non-alcoholic fatty liver disease

  2014cites this paper
• Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.

  2014cites this paper
• Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.

  2014cites this paper
• Obesity and nonalcoholic fatty liver disease

  2014cites this paper
• Diagnosis and management of lipodystrophy: a practical update

  2014cites this paper
• [Non-alcoholic fatty liver: position document of the Catalan Society of Gastroenterology].

  2014cites this paper
• Best Practice & Research Clinical Endocrinology & Metabolism

  2013cites this paper
• Diabete mellito tipo 2: è tempo per una terapia personalizzata? Il Diabete

  2013cites this paper
• Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease

  2013influential citation
• Novel approaches to the pharmacotherapy of obesity.

  2013cites this paper
• Nonalcoholic fatty liver disease: current and potential therapies.

  2013cites this paper
• Hydroximic acid derivatives: pleiotropic HSP co-inducers restoring homeostasis and robustness.

  2013cites this paper
• Abnormal Uterine Bleeding, Health Status, and Usual Source of Medical Care: Analyses Using the Medical Expenditures Panel Survey

  2013cites this paper
• Purple sweet potato color attenuates hepatic insulin resistance via blocking oxidative stress and endoplasmic reticulum stress in high-fat-diet-treated mice.

  2013cites this paper
• Fatty Liver Increases the Association of Metabolic Syndrome With Diabetes and Atherosclerosis

  2013cites this paper
• Hepatic function and the cardiometabolic syndrome

  2013cites this paper
• Drugs improving insulin resistance for non‐alcoholic fatty liver disease and/or non‐alcoholic steatohepatitis

  2013cites this paper
• Biomarkers for early detection of non-alcoholic steatohepatitis: implications for drug development and clinical trials.

  2013cites this paper
• Pharmacological agents for NASH

  2013cites this paper
• The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis

  2013cites this paper
• Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae.

  2013cites this paper
• Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD.

  2013cites this paper
• Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease.

  2013cites this paper
• A 2012 clinical update for internists in adult nonalcoholic fatty liver disease.

  2012cites this paper
• The role of gut hormones in controlling the food intake: what is their role in emerging diseases?

  2012influential citation
• Female Mice Are More Susceptible to Nonalcoholic Fatty Liver Disease: Sex-Specific Regulation of the Hepatic AMP-Activated Protein Kinase-Plasminogen Activator Inhibitor 1 Cascade, but Not the Hepatic Endotoxin Response

  2012cites this paper
• Non-Alcoholic Fatty Liver Disease

  2010influential citation